Nature Medicine, Published online: 07 April 2026; doi:10.1038/s41591-026-04307-8 In a phase 1 basket trial, the small interfering RNA zodasiran, targeting ANGPTL3, lowered triglycerides in patients with severe hypertriglyceridemia and lowered both triglycerides and low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolemia.
Nature Medicine published a clinical update in Research Highlights on 07 Apr 2026.
The item focuses on Zodasiran for cholesterol and triglyceride lowering in patients with hyperlipidemia: final report of phase 1 basket trial.
Review the original article for the full source wording and details.